Literature DB >> 22313239

Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa.

Sarah Lowick1, Shobna Sawry, Tammy Meyers.   

Abstract

Neurodevelopmental delay has been documented in up to 97.5% of HIV-infected children in Soweto who were not yet on antiretroviral treatment (ART). With growing numbers of children in South Africa being successfully treated with ART, the effects of ART on neurocognitive functioning in children require investigation. The objective of this study was to determine the extent of neurodevelopmental delay in stable HIV-infected preschool children (aged five to six years) receiving ART and compare it to an apparently healthy (unconfirmed HIV-status) group of preschool children. Thirty HIV-infected preschool children (virologically and immunologically stable on ART for more than one year) were conveniently sampled from 350 eligible children on ART at the Harriet Shezi Children's Clinic in Soweto, Johannesburg. The comparison group comprised 30 well-nourished preschool children attending the Lilian Ngoyi Primary Health Care Clinic in Soweto for routine immunizations. Each child was assessed using the Griffiths Mental Development Scales-Extended Revised Version (GMDS-ER), at a single point in time. The overall developmental z-scores on GMDS-ER were <-2 (indicating severe delay) in 27 (90%) children in the HIV-infected group compared to 23 (76%) in the comparison group (p = 0.166). Mental handicap (overall GQ < 70) was evident in 46.7% of children in the HIV-infected group compared to 10% in the comparison group (p = 0.002). There was a 7.88-fold increased likelihood of severe delay in the HIV infected group. The HIV-infected group and comparison group had significantly different (p = 0.001) mean overall GQ scores of 70 (95% CI: 66.0-74.0) and 78 (95% CI: 75.6-80.5), respectively, with lower mean scores in the HIV-infected group in all individual domains. Early initiation of ART in HIV-infected infants may improve cognitive functioning among this group; however, intervention strategies which optimize early cognitive development for all children in the area need to be urgently considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313239     DOI: 10.1080/13548506.2011.648201

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  22 in total

1.  Impact of HIV and Atiretroviral Therapy on Neurocognitive Outcomes Among School-Aged Children.

Authors:  Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Joseph Kagaayi; Godfrey Kigozi; David Serwadda; Avy Violari; Ronald H Gray
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

Review 2.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

3.  Early viral suppression improves neurocognitive outcomes in HIV-infected children.

Authors:  Claudia S Crowell; Yanling Huo; Katherine Tassiopoulos; Kathleen M Malee; Ram Yogev; Rohan Hazra; Richard M Rutstein; Sharon L Nichols; Renee A Smith; Paige L Williams; James Oleske; William J Muller
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

4.  Addressing the socio-development needs of adolescents living with HIV/AIDS in Nigeria: a call for action.

Authors:  Morenike Folayan; Brandon Brown; Abigail Harrison
Journal:  Afr J Reprod Health       Date:  2014-09

Review 5.  Biomedical risk, psychosocial influences, and developmental outcomes: lessons from the pediatric HIV population in Africa.

Authors:  Amina Abubakar
Journal:  New Dir Child Adolesc Dev       Date:  2014

6.  Patterns of emotional and behavioural challenges in children living with HIV: results from a hyperendemic South African setting.

Authors:  Kusturi Pillay; Andrew Tomita; Saeeda Paruk
Journal:  Vulnerable Child Youth Stud       Date:  2021-01-05

7.  S-EQUOL: a neuroprotective therapeutic for chronic neurocognitive impairments in pediatric HIV.

Authors:  Kristen A McLaurin; Hailong Li; Anna K Cook; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2020-09-01       Impact factor: 2.643

8.  White matter signal abnormalities in children with suspected HIV-related neurologic disease on early combination antiretroviral therapy.

Authors:  Christelle Ackermann; Savvas Andronikou; Barbara Laughton; Martin Kidd; Els Dobbels; Steve Innes; Ronald van Toorn; Mark Cotton
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

9.  Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study.

Authors:  Thanyawee Puthanakit; Jintanat Ananworanich; Saphonn Vonthanak; Pope Kosalaraksa; Rawiwan Hansudewechakul; Jasper van der Lugt; Stephen J Kerr; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Jurai Wongsawat; Wicharn Luesomboon; Ung Vibol; Kanchana Pruksakaew; Tulathip Suwarnlerk; Tanakorn Apornpong; Kattiya Ratanadilok; Robert Paul; Lynne M Mofenson; Lawrence Fox; Victor Valcour; Pim Brouwers; Kiat Ruxrungtham
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

Review 10.  The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents.

Authors:  Annette H Sohn; Rohan Hazra
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.